Additionally, BCLAF1 has been identified as a potential therapeutic target, with the efficacy of immune checkpoint blockade (ICB) treatment potentially enhanced in HCC cases exhibiting high BCLAF1 expression in vitro86. The gene discussed is BCLAF1; the disease is hepatocellular carcinoma.